Akamis Bio Reports Promising Results from Phase 1b Study of NG-350A in Rectal Cancer
Akamis Bio has announced encouraging preliminary results from its Phase 1b FORTRESS study of NG-350A, an oncolytic immunotherapy, in combination with chemoradiotherapy (CRT) for treating mismatch repair-proficient locally advanced rectal cancer (LARC). The study showed a composite response rate of 50% among the first 10 patients, with no serious adverse events related to NG-350A. This response rate is significantly higher than the expected 25% for CRT alone. The study aims to improve treatment outcomes for LARC patients, potentially offering a non-operative approach and organ preservation. 
